- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Patent holdings for IPC class C07K 16/24
Total number of patents in this class: 6781
10-year publication summary
|
440
|
439
|
466
|
535
|
565
|
592
|
515
|
509
|
492
|
349
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Biotech, Inc. | 1561 |
243 |
| Novartis AG | 10721 |
214 |
| Abbvie Inc. | 1806 |
129 |
| Amgen Inc. | 4108 |
120 |
| Eli Lilly and Company | 3902 |
114 |
| Genentech, Inc. | 4009 |
109 |
| Regeneron Pharmaceuticals, Inc. | 4355 |
102 |
| MedImmune Limited | 620 |
95 |
| Sanofi | 4097 |
83 |
| Immatics Biotechnologies GmbH | 1153 |
76 |
| Ablynx N.V. | 401 |
67 |
| Hoffmann-La Roche Inc. | 3478 |
65 |
| F. Hoffmann-La Roche AG | 7948 |
62 |
| Chugai Seiyaku Kabushiki Kaisha | 1370 |
60 |
| ZymoGenetics, Inc. | 186 |
60 |
| Boehringer Ingelheim International GmbH | 4640 |
57 |
| The Regents of the University of California | 20108 |
52 |
| National University of Singapore | 2480 |
51 |
| Bristol-myers Squibb Company | 4849 |
48 |
| Cedars-Sinai Medical Center | 1165 |
48 |
| Other owners | 4926 |